Skip to content

Electroacupuncture Intervention in Catheter Ablation of Atrial Fibrillation

A Randomized Control Trial to Determine Whether Electroacupuncture(EA) Intervention With Morphine Can Reduce the Intraoperative Pain and Early Post-operative Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05575544
Enrollment
200
Registered
2022-10-12
Start date
2022-10-11
Completion date
2023-10-13
Last updated
2022-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Catheter Ablation

Brief summary

This is a randomized control trial to determine whether electroacupuncture(EA) intervention with Morphine can reduce the intraoperative pain and early post-operative complications in patients undergoing catheter ablation of atrial fibrillation.

Interventions

PROCEDUREAcupuncture plus morphine

The acupuncture was combined with intravenous use of morphine to achieve anesthesia during the ablation procedure

Sponsors

Shanghai Chest Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Aged 18 to 80 years old; 2. Atrial fibrillation 3. Nonresponse or intolerance to ≥1 antiarrhythmic drug.

Exclusion criteria

1. A history of allergy to acupuncture; 2. With uncontrolled congestive heart failure; 3. Having significant valvular disease; 4. Having moderate-to-severe pulmonary hypertension; 5. With myocardial infarction or stroke within 6 months of screening; 6. With Significant congenital heart disease; 7. Ejection fraction was \<40% measured by echocardiography; 8. Allergic to contrast media; 9. Contraindication to anticoagulation medications; 10. Severe pulmonary disease e.g. restrictive pulmonary disease, chronic obstructive disease (COPD); 11. Left atrial thrombus; 12. Having any contraindication to right or left sided heart catheterization

Design outcomes

Primary

MeasureTime frameDescription
The severity of intraprocedural pain during the catheter ablation procedureup to 1 month after enrollmentPain was assessed by Visual Analogue Score (VAS).VAS is one of the commonly used pain scoring standards. The full name is the visual simulation scoring method. The pain is divided into 10 points, 2 points for no pain, 10 points for severe pain, and the middle part for different degrees of pain.To compare the scores of patients during pulmonary vein isolation procedure.
The severity of intraprocedural nausea during the catheter ablation procedureup to 1 month after enrollmentThe incidence of nausea, vomiting and retching within 12 hours after operation was recorded, including 3 dimensions of symptom experience time, frequency and severity, with 8 items in total. 0\ 4 points shall be used for 5 grades. 0 points means none at all, and 4 points means very serious and intolerable.

Secondary

MeasureTime frameDescription
The dose of morphine used during the catheter ablation procedureup to 1 month after enrollmentTo compare the dose of morphine used during pulmonary vein isolation procedure.
the change of blood pressure during the catheter ablation procedureup to 1 months after enrollmentRecord the changes of blood pressure during the catheter ablation procedure
Change of the the radio of IL6/IL10 before and after the ablation procedureup to 1 months after enrollment
Incidence of complicationsup to 6 months after enrollmentdeath, atrio-esophageal fistula, cardiac tamponade/perforation, myocardial infarction, stroke/cerebrovascular accident, thromboembolism, diaphragmatic paralysis, pneumothorax, pleural effusion, heart block, pulmonary vein stenosis, pulmonary edema, left atrial thrombus, pericarditis and major vascular access complication or bleeding

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026